OptimizeRx Corporation
OPRX
$7.77
$0.628.67%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.31M | 18.81M | 19.69M | 28.37M | 16.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.31M | 18.81M | 19.69M | 28.37M | 16.33M |
| Cost of Revenue | 7.86M | 7.11M | 7.49M | 10.53M | 6.53M |
| Gross Profit | 13.45M | 11.70M | 12.20M | 17.84M | 9.80M |
| SG&A Expenses | 13.43M | 14.38M | 16.17M | 15.15M | 12.89M |
| Depreciation & Amortization | 1.10M | 1.07M | 1.07M | 1.01M | 467.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.38M | 22.56M | 24.72M | 26.68M | 19.88M |
| Operating Income | -1.07M | -3.75M | -5.03M | 1.69M | -3.55M |
| Income Before Tax | -9.94M | -5.10M | -6.56M | -11.74M | -2.87M |
| Income Tax Expenses | -817.00K | -1.09M | 344.00K | -7.60M | -- |
| Earnings from Continuing Operations | -9.12M | -4.01M | -6.90M | -4.14M | -2.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.12M | -4.01M | -6.90M | -4.14M | -2.87M |
| EBIT | -1.07M | -3.75M | -5.03M | 1.69M | -3.55M |
| EBITDA | -132.00K | -2.81M | -4.08M | 2.90M | -3.15M |
| EPS Basic | -0.50 | -0.22 | -0.38 | -0.23 | -0.17 |
| Normalized Basic EPS | -0.08 | -0.17 | -0.23 | 0.03 | -0.11 |
| EPS Diluted | -0.50 | -0.22 | -0.38 | -0.24 | -0.17 |
| Normalized Diluted EPS | -0.08 | -0.17 | -0.23 | 0.03 | -0.11 |
| Average Basic Shares Outstanding | 18.32M | 18.26M | 18.17M | 17.78M | 16.64M |
| Average Diluted Shares Outstanding | 18.32M | 18.26M | 18.17M | 17.78M | 16.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
